Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
MAYNF MAYNE PHARMA GROUP LIMITED
0.150
-0.006-3.85%
YOY
Do not show
Hide blank lines
Financial Ratios
Efficiency Ratios TTM
Efficiency Ratios
Profitability Ratios TTM
Financial Health Ratios
GrowthRatios
Growth Ratios

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment is involved in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty Products segment includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment manufactures and sells branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.
CEO: Mr. Shawn Patrick O’Brien
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist